Posted by Michael Wonder on 24 Sep 2024
Elevation Oncology receives fast track designation from the FDA for EO-3021 for the treatment of adult patients with advanced or metastatic gastric or gastro-oesophageal junction cancer expressing Claudin 18.2
23 September 2024 - Elevation Oncology today announced that the US FDA has granted fast track designation to EO-3021, a differentiated antibody drug conjugate, for the treatment of patients with advanced or metastatic gastric and gastro-oesophageal junction cancer expressing Claudin 18.2 that has progressed on or after prior therapy.
EO-3021 is a differentiated, clinical-stage antibody drug conjugate with best in class potential comprised of an immunoglobulin G1 (IgG1) monoclonal antibody that targets Claudin 18.2 and a monomethyl auristatin E payload with a cleavable linker that is site-specifically conjugated to Glutamine 295 providing a drug to antibody ratio of 2.
